Zydus Cadila has received the final approval from the US FDA to market carbidopa tablets, 25 mg. It is used with a combination levodopa/carbidopa product to treat symptoms of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). It will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.

The group now has more than 190 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.